UX023: Phase I/II data

The open-label, dose-escalation, U.S. and Canadian Phase I/II INT-001 trial in 28 adults with XLH showed that once-monthly 0.05-0.6 mg/kg doses of subcutaneous KRN23 increased urinary phosphorus reabsorption, serum phosphorus levels and 1,25 dihydroxy vitamin D levels. KRN23